Context: Lymphatic fi lariasis or elephantiasis a serious public health problem in India. Millennium Development Goals and National Health Policies purport to eliminate fi lariasis by 2015. The concept of mass drug administration (MDA) is to approach every individual in the target community and administer annual single dose of anti-fi larial drugs (DEC or DEC+Albendazole). Aims: 1. Assess the coverage and compliance to MDA in the district. 2. Assess the awareness of elephantiasis among benefi ciaries. 3. Assess the knowledge of drug distributors about fi lariasis and the MDA program. Materials and Methods: This cross-sectional study was conducted in one urban and three rural clusters in Uttara Kannada district of Karnataka for the period of one week. A total of 50 houses were selected in each cluster by systematic random sampling method and data were collected in a structured proforma by interview technique. Statistical Analysis Used: Descriptive statistics such as percentage, mean, and standard deviation. Results: Among 1,022 benefi ciaries, the overall coverage of MDA was 82.3%. Compliance among those who had received the tablets was 52.1%. Effective coverage rate was 42.9%. The compliance rate was signifi cantly higher in rural areas [376 (58.6%)] compared to urban areas [62 (31.0%)]. The most common reason quoted for not consuming drugs was "Don't want" (50.4%). A total of 56% of the respondents were aware of the elephantiasis disease and MDA program. Conclusions: Even though there was high coverage of MDA in Uttara Kannada district, compliance and effective coverage rates were found to be poor.
INTRODUCTION
Filariasis has been a major public health problem in India next only to malaria. The disease was recorded in India as early as the sixth century BC by the famous Indian physician Susruta in his book 'Susruta Samhita'. Although fi lariasis is not lethal, it causes debility and imposes severe social and economic burden on affected individuals, their families, and communities. [1, 2] Over 600 million people living in 250 districts across 20 states/Union Territories of India are endemic for the disease. Three-fourths of those at risk live in rural areas. An estimated 49 million individuals in India are infected with lymphatic fi lariasis. Of these, over 23 million people suffer from chronic forms of fi lariasis. Wuchereria bancrofti is the species that causes 99.4% of all cases of fi lariasis, while Brugia malayi is responsible for 0.6% of the problem. In Karnataka, 13.28 million people from 39 Talukas of 8 districts live in the endemic area; of these, 10.14 million are from rural areas.
National Health Policy (2002) has set the goal of elimination of lymphatic fi lariasis in India by 2015. Mass drug administration of a single dose of DEC was launched at the National Filaria Day (NFD) on June 5, 2004 , by the Government of India. Co-administration of DEC with Albendazole, which was initiated in 2008, was expanded to all districts in 2009. [3] A high coverage of more than 85% in endemic areas, which is sustained for fi ve years, is required to achieve interruption of transmission and elimination of the disease in India. Even though the drug distribution in the country is more than 85%, people who actually consume the drugs widely vary on the geographical and socio-cultural bases. The major challenge is drug delivery in urban areas and low priority given to lymphatic fi lariasis. [4] With this background, following the instructions given by Regional offi ce, Ministry of Health and Family Welfare, Government of India, this study was conducted in Uttara Kannada district, Karnataka, with the following objectives: 1. Assess the coverage and compliance to mass drug administration (MDA) in the district; 2. Assess awareness regarding elephantiasis among benefi ciaries; 3. Assess the knowledge of drug distributors on the fi lariasis and MDA program.
MATERIALS AND METHODS
This cross-sectional study was conducted in Uttara Kannada, one of the coastal districts of Karnataka, India, during April 2013 for a period of one month. The line listing of lymphedema cases for the year 2012 was collected from the District Filaria Offi ce and the Talukas were arranged in the ascending order of the incidence of lymphedema cases. One Taluka was selected for each low, medium, and high prevalence. One primary health center was selected by each Taluka and one subcenter from each PHC was selected randomly by lottery method. The same method was used for the selection of village from each of these subcenters for the household survey. As one ward was to be covered in urban areas, all wards in Kumuta -a town with the highest endemicity -were line listed from this area. One ward was selected randomly by lottery method for the household survey. Thus, one urban and three rural clusters were selected as per the instructions provided by the Regional Offi ce, Ministry of Health and Family Welfare, Government of India. Data on the knowledge of drug distributors regarding fi lariasis was collected at the subcenter and the village level in a pre-tested structured proforma, which includes basic information a drug distributor should be having, for instance, whether they have ever heard of fi lariasis, the purpose of MDA program, and probable side effects of drugs used in MDA by interview technique. Same proforma was also used by authors for assessing the knowledge of drug distributors at Bidar district, Karnataka, in 2011. [5] House-to-house survey was conducted after a fortnight of drug distribution in the villages and wards selected by the abovementioned technique, for which the center of the village was identifi ed by the help of a resident of the village; from this center, the four directions were identifi ed and numbered. One direction was chosen randomly and a walkthrough survey was done to note the average number of houses in the street. Investigators randomly selected the fi rst house on the road, and subsequently, every fi fth house was selected by a systematic random sampling technique. A total of 50 houses were covered in each village and ward. Data regarding socio-demographic characteristics, coverage, and compliance to MDA and awareness regarding fi lariasis among benefi ciaries were collected in a pre-tested structured proforma by interviewing the adult responsible respondent aged 18-60 years; the information was gathered after explaining the purpose of the survey and showing a fl ashcard containing an image of elephantiasis case, DEC, and albendazole tablets. The interview was conducted by one Assistant Professor and two second-year postgraduate students of Community Medicine who had received a one-day training on MDA program evaluation in the Regional Offi ce of Health and Family Welfare, Government of India, Bangalore.
Statistical analysis
Data collected were entered in Microsoft excel-2010 and analyzed using SPSS version 18. Descriptive statistical measures such as percentage, mean, and standard deviation were applied. Inferential statistical test such as Chi-square test was applied for assessing the association of coverage, compliance, and effective coverage rate with locality. Associations were interpreted to be statistically signifi cant at P < 0.05.
RESULTS

General characteristics
Among 200 households comprising 1,022 benefi ciaries (excluding children aged less than 2 years, pregnant women, and elderly suffering from chronic illnesses) surveyed, the majority [788 (77.1%)] were in the age group of 15-60 years, while 507 (49.6%) were male and 515 (50.4%) female. 
Coverage and compliance of MDA
Awareness of fi lariasis and MDA among drug distributors
Among 21 drug distributors surveyed from 4 clusters, 16 (76.2%) were aware of fi lariasis and 8 (38.1%) had seen a case of lymphatic fi lariasis in their vicinity. A total of 14 (66.7%) drug distributors were aware of the purpose and rationale of the MDA program, 16 (76.2%) were aware of proper dosage of MDA, and 12 (57.1%) were aware of the possible adverse effects of MDA.
DISCUSSION
Mass drug administration against lymphatic filariasis is an ambitious program by the government toward eliminating this chronic scourge from the country by 2015. The present study was conducted in one of the coastal districts of Karnataka, which is endemic for the disease. The coverage of MDA observed in the present study was satisfactory (82.3%). The sustained high level of coverage (85%) for a minimum of fi ve years is essential to achieve the interruption of transmission and elimination of the disease. [3, 4] The coverage observed in the present study was similar to the results of the study conducted by B. G. Ranganath in Gulbarga district of Karnataka (85%), [6] Ashwini Kumar in a neighboring Udupi district (73.4%), [7] Pradeep Kumar et al. in Gujarat state (85.2%), [4] and T. Mahalakshmy at Puducherry (76.2%). [8] In contrast, Dr. D. M. Koradhanyamath in Bidar district of Karnataka observed the coverage to be 62.3%. The compliance of MDA is a more sensitive indicator than the coverage because this indicates the actual consumption of tablets by the benefi ciaries. In the present study, the compliance among those who had received the tablets was 52.1%; this was similar to the observations made by B. G. Ranganath in Gulburga, [6] where the compliance was 32.7% and Dr. D. M. Koradhanyamath [5] in Bidar district (60.4%). On the other hand, the compliance was as high as 85.6% in an independent external evaluation of MDA in Udupi district. [9] Similar observations were made by Pradeep Kumar [4] in Gujarat state and by T. Mahalakshmy at Puducherry, [8] where compliance was 89% and 88.7%, respectively. It is clear from the above results that even though the coverage in Uttara Kannada district was high, compliance was below standard. Effective coverage rate, which tests the actual drug intake against the total number of benefi ciaries, was also as low as 42.8% in contrast to the observations made by Pradeep Kumar et al at Gujarat (75.8%). [4] These fi ndings can be attributed to the fact that there is no seriousness about the disease as well as the strategy among benefi ciaries. It is evident from the fact that the majority of the benefi ciaries who did not consume the tablets quoted the reasons for non-consumption as "don't want to consume", "fear of adverse drug reactions", and "doubtful benefi t on consumption," all of which are pure misconceptions. One of the best strategies for improving compliance, which has failed in the present district, is consumption of tablets in front of the drug distributors. Many benefi ciaries attributed this to the most avoidable reasons such as not have consumed food at the time of drug distribution and not being present at home when the drugs were distributed, which showed the lack of information among the people regarding the days and timings of drug distribution. 
